Project S.T.O.P (Stop the Over-ordering of Platelets): An initiative to Reduce Platelet Wastages for Pediatric Open-heart Surgeries
Due to a national policy change in the management of unused platelets units from September 2018, there was a drastic increase in the number of platelet units wasted in our institution. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - March 14, 2023 Category: Hematology Authors: X Zhong, YJA Tan, M Nakao, IL Chan, ML Heng, SMA Tan, YL Ng, JCM Lam Source Type: research
Plasma Transfusion in Critically Ill Patients With Abnormal Coagulation Tests Before Invasive Procedures: A Propensity-adjusted Cohort Study
To evaluate the association between plasma transfusion and bleeding complications in critically ill patients with an elevated international normalized ratios undergoing invasive procedures. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - March 11, 2023 Category: Hematology Authors: Qi Ren, Jie Zhao, Xuehua He, Li Su, Juchuan Chai, Lingling Bai, Zhengcai Ao, Caixia Wu, Xiaoyu Guan, Yudi Xie, Yujie Kong, Ling Li, Zhong Liu Source Type: research
Effects of Cytokine Hemadsorption as Salvage Therapy on Common Laboratory Parameters in Patients with Life-threatening COVID-19
This study aims to investigate the experience of salvage HA therapy and the effect of HA on routine laboratory tests. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - March 11, 2023 Category: Hematology Authors: Serhat Uysal, Mustafa Merter, Ay şe Uysal, Ayhan Akbulut Source Type: research
Nephrolithiasis in Two Patients on Iron Chelation Therapy: A Case Report
In this report, we describe two pediatric patients diagnosed with nephrolithiasis while undergoing treatment with the chelating agents deferasirox, deferiprone, and deferoxamine for iron overload secondary to repeat blood transfusion (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - March 10, 2023 Category: Hematology Authors: Hannah Dillon, Zo ë Baker, Adam Pena, Yuding Wang, Helal Syed, Scott Sparks Source Type: research
Assessment of the impact of pathogen reduction technologies on the neutralizing activity of COVID-19 convalescent plasma.
COVID-19 convalescent plasma (CCP) could improve the clinical outcome of COVID-19 patients when high-titer CCP is administered in early stages of disease. However, CCP donors have a risk profile like first-time donors, pathogen reduction treatment (PRT) may mitigate such risk but should not impact CCP quality. The current study aims to assess the impact of PRT-technologies available in Saudi Arabia on the neutralizing activity of CCP. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - March 3, 2023 Category: Hematology Authors: Salwa Hindawi, Tarek Elgemmezi, Sherif El-Kafrawi, Hani Samadani, Myasin Tilmisani, Omar Assiri, Mohammad Raml, Esam Azhar, Maha Badawi Source Type: research
Reduction of Anti-A and Anti-B Isoagglutinin Titers of Group O Whole Blood Units Employing an ABO Antibody Immune Adsorption Column
Massive hemorrhage is a leading cause of death from trauma. There is growing interest in group O whole blood transfusions to mitigate coagulopathy and hemorrhagic shock. Insufficient availability of low-titer group O whole blood is a barrier to routine use. We tested the efficacy of the Glycosorb ® ABO immunoadsorption column to reduce anti-A/B titers in group O whole blood. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - March 3, 2023 Category: Hematology Authors: Gaurav K. Gupta, Kelly Henrichs, Kurt Nilsson, Stephen Wagner, Bethany Brown, Debra Masel, Mark L. Gestring, Michael A. Vella, Majed A. Refaai, Neil Blumberg Source Type: research
Editorial by Chair of the Scientific Program Committee
September 2022, finally, six years after the Paris Meeting in 2016, the World Apheresis Association (WAA) was able to organize a scientific meeting again. Generally, the WAA hosts usually in partnership with one or more member societies a scientific and educational congress every two calendar years. However, the meeting in 2018 was cancelled because of organizational reasons and the planned meeting in 2020 in Istanbul had to be postponed because of the COVID-19 pandemic. In 2022, the scientific committee succeeded in composing an interesting program with state of the art educational and scientific themes, brought by excell...
Source: Transfusion and Apheresis Science - March 1, 2023 Category: Hematology Authors: Hans Vrielink Tags: Editorial Source Type: research
Biomarkers of response and prognosis in TTP
Since first described, Thrombotic thrombocytopenic purpura (TTP) has been a very uncommon disease with a long history marked by periodic episodes in which new evidence and treatments have markedly changed the course of this once fatal disease. Some of the most recent developments offer novel and exciting approaches to both our understanding and management of TTP and indeed, to thrombosis in general. This paper aims to review some of the significant events leading to the relatively good outcome which patients can expect today. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - March 1, 2023 Category: Hematology Authors: Gail Rock Source Type: research
Thrombotic thrombocytopenic purpura in caplacizumab era – An individualized approach
Thrombotic thrombocytopenic purpura (TTP) is a rare disease characterized by a severe deficiency ( 90 % to (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 28, 2023 Category: Hematology Authors: Ravi Sarode Source Type: research
Therapeutic plasma exchange-free treatment for first-episode TTP: A systematic review
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy (TMA), and therapeutic plasma exchange (TPE) is currently the standard treatment. However, TPE sometimes cannot be implemented. The aim of this study was to systematically review patients with a first TTP episode who were treated without TPE. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 28, 2023 Category: Hematology Authors: Jiang Wang, Fu Cheng, Yingying Niu, Lingli Yan, Jiaheng Li, Bin Tan, Li Qin Source Type: research
Spotlight on the impact of transfusion support, the detrimental influence of blood donation microbiomes on hematological immune-related toxicities, and the sustained efficacy and survival outcomes of immune checkpoint inhibitors ’ treated cancer patients
The main objective of the 2022 issues of the What ’s Happening section was to encourage an international team of experts to provide the readers with concise reviews of topics of current interest on strategies for risk assessment, predictive diagnosis, and patient management to bring, today, what will be tomorrow’s news. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 28, 2023 Category: Hematology Authors: Jerard Seghatchian Source Type: research
“Thrombotic Thrombocytopenic Purpura in Caplacizumab Era – an Individualized Approach.”
Thrombotic thrombocytopenic purpura (TTP) is a rare disease characterized by a severe deficiency (90% to (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 28, 2023 Category: Hematology Authors: Ravi Sarode Source Type: research
EDITORIAL COMMENTARY: WHAT ’S HAPPENING? [TRASCI 62.2] Spotlight on the impact of transfusion support, the detrimental influence of blood donation microbiomes on hematological immune-related toxicities, and the sustained efficacy and survival outcomes of immune checkpoint inhibitors’ treated cancer patients.
The main objective of the 2022 issues of the What ’s Happening section was to encourage an international team of experts to provide the readers with concise reviews of topics of current interest on strategies for risk assessment, predictive diagnosis, and patient management to bring, today, what will be tomorrow’s news. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 28, 2023 Category: Hematology Authors: Jerard Seghatchian Source Type: research
Therapeutic plasma exchange-free treatment for first-episode TTP ：a systematic review
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic, microangiopathy (TMA), and therapeutic plasma exchange (TPE) is currently the, standard treatment. However, TPE sometimes cannot be implemented. The aim of this, study was to systematically review patients with a first TTP episode who were treated, without TPE. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 28, 2023 Category: Hematology Authors: Jiang Wang, Fu Cheng, Yingying Niu, Lingli Yan, Jiaheng Li, Bin Tan, Li Qin Source Type: research
Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient ’s safety and survival outcome:A systematic narrative appraisal of where we are now!
Classically, patients with solid and hematologic malignancies have been treated with a combination of chemotherapy with or without a holistic targeted strategy using approved conventional therapy.While the evidence-based use of Immunomodulatory drugs and Immune checkpoint inhibitors (ICIs), including those targeting the PD-1, PD-L1 and CTLA-4, have reshaped the treatment paradigm for many malignant tumors and significantly stretched the life expectancy of patients, as for any interventional therapy, the rise in ICI applications, was associated with the observation of more immune-related hematological adverse events. (Sourc...
Source: Transfusion and Apheresis Science - February 25, 2023 Category: Hematology Authors: Mohamed Shouman, Hadi Goubran, Jerard Seghatchian, Thierry Burnouf Source Type: research
